Heel Inc. Offers Safe and Effective Homeopathic Alternative to Controversial Cox-2 Inhibitors
Posted on: Tuesday, 23 August 2005, 15:00 CDT
ALBUQUERQUE, N.M., Aug. 23 /PRNewswire/ -- Heel Inc. announces the availability of a safe alternative to conventional and controversial drugs in treating mild to moderate arthritis. This announcement concerns more than 20 million Americans affected by osteoarthritis today. The U.S. Food and Drug Administration announced in July it was requesting manufacturers of Non-Steroidal Anti-Inflammatory Drugs, NSAIDs, to make label changes to include warnings of potential for increased risk of cardiovascular events and potentially life-threatening gastrointestinal bleeding associated with their use. The full announcement is available on the FDA's Web site. This news comes on the heels of Merck & Co. urging patients who were taking Vioxx(R) to contact their physicians to discuss discontinuing its use and to seek possible alternative treatments.
An alternative to these risky medications already exists. Zeel(R) is made up of a combination of natural active ingredients and provides safe and effective relief of mild to moderate arthritic symptoms. It provides temporary relief of joint pain, improves joint function and stimulates normal cartilage performance. Studies have proven it is natural, non-habit forming, and safe and effective for long-term treatment. Furthermore, it has no known interactions with other medications.
Osteoarthritis affects nearly 20 million people in the United States annually. The goal behind pharmaceutical therapy for arthritis is to relieve pain, improve mobility and prevent progression of inflammation. To achieve these results, analgesic and anti-inflammatory medications such as NSAIDs, non-selective Cox-1 inhibitors and selective Cox-2 inhibitors are commonly prescribed. Patients taking Cox-2 inhibitors have been reported to experience undesirable effects including cardiovascular problems, gastric complaints, edema, diarrhea, vomiting and dizziness. Zeel has long been proven with over 50 years of worldwide use and more than a decade of research. In fact, in a recent study comparing the efficacy of Zeel to Cox-2 inhibitors, there was no report of adverse events for the patients who used Zeel.
Heel Inc. has several clinical studies on Zeel. Overall, the studies show the product is safe and as effective as Cox-1 and Cox-2 inhibitors. For further information on the studies please visit the Web site, http://www.zeelusa.com/. Zeel is available in ointment, tablet, oral vial and prescription injectable form and is virtually side-effect free. Persons with known hypersensitivity to Rhus toxicodendron (poison oak) should be aware that it could result in a rash. Beyond its proven safety and effectiveness, its lower cost greatly reduces the need for secondary medication to control adverse side effects. It can also help reduce the cost of long-term arthritis management.
Heel Inc. is the U.S. subsidiary of Heel, which is one of the world's largest homeopathic pharmaceutical manufacturers with distribution in over 60 countries. For further information on Zeel and other Heel Inc. products visit our Web site, http://www.heelusa.com/.
Heel Inc.
CONTACT: Gibson Archer, Retail Sales & Marketing Manager, ext. 2955,garcher@HeelUSA.com, or Joan Sullivan, Marketing Coordinator, ext. 2952,jsullivan@HeelUSA.com, both of Heel Inc., +1-800-621-7644
Web site: http://www.zeelusa.com/
Web site: http://www.heelusa.com/
Source: PRNewswire
Related Articles
- Cox-2 Inhibitors Not Safer for Stomach
- THE PROFNET WIRE: HEALTH & MEDICINE - Cox-2 Inhibitors/Tanning Beds
- Majority of Patients Have Discontinued Use of COX-2 Inhibitors
- Renewed Scrutiny for Vioxx, Other COX-2 Inhibitors
- Cox-2 Drugs Overprescribed for Years, Study Says
- A Look at Drugs Known As Cox-2 Inhibitors
- Research And Markets: Despite The Withdrawal Of Vioxx - Rofecoxib - From The Market In November 2004, Considerable Activity Continues To Be Reported Relating To The Development Of COX-2 Inhibitors
- Key Differences in Cardiovascular Risk Among COX-2 Inhibitors Identified
- COX-2 Inhibitor Pulled Off Market
User Comments (0)

RSS Feeds